This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jorgensen, J. H.
Right arrow Articles by Tenover, F. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jorgensen, J. H.
Right arrow Articles by Tenover, F. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2000, p. 2962-2968, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Activities of Clinafloxacin, Gatifloxacin, Gemifloxacin, and Trovafloxacin against Recent Clinical Isolates of Levofloxacin-Resistant Streptococcus pneumoniae

J. H. Jorgensen,1,* L. M. Weigel,2 J. M. Swenson,2 C. G. Whitney,3 M. J. Ferraro,4 and F. C. Tenover2

Department of Pathology, The University of Texas Health Science Center, San Antonio, Texas 782291; Hospital Infections Program2 and Division of Bacterial and Mycotic Diseases,3 Centers for Disease Control and Prevention, Atlanta, Georgia 30333; and The Massachusetts General Hospital, Boston, Massachusetts 021144

Received 19 May 2000/Returned for modification 8 July 2000/Accepted 2 August 2000

The activities of two investigational fluoroquinolones and three fluoroquinolones that are currently marketed were determined for 182 clinical isolates of Streptococcus pneumoniae. The collection included 57 pneumococcal isolates resistant to levofloxacin (MIC >=  8 µg/ml) recovered from patients in North America and Europe. All isolates were tested with clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, and trovafloxacin by the National Committee for Clinical Laboratory Standards broth microdilution and disk diffusion susceptibility test methods. Gemifloxacin demonstrated the greatest activity on a per gram basis, followed by clinafloxacin, trovafloxacin, gatifloxacin, and levofloxacin. Scatterplots of the MICs and disk diffusion zone sizes revealed a well-defined separation of levofloxacin-resistant and -susceptible strains when the isolates were tested against clinafloxacin and gatifloxacin. DNA sequence analyses of the quinolone resistance-determining regions of gyrA, gyrB, parC, and parE from 21 of the levofloxacin-resistant strains identified eight different patterns of amino acid changes. Mutations among the four loci had the least effect on the MICs of gemifloxacin and clinafloxacin, while the MICs of gatifloxacin and trovafloxacin increased by up to six doubling dilutions. These data indicate that the newer fluoroquinolones have greater activities than levofloxacin against pneumococci with mutations in the DNA gyrase or topoisomerase IV genes. Depending upon pharmacokinetics and safety, the greater potency of these agents could provide improved clinical efficacy against levofloxacin-resistant pneumococcal strains.

* Corresponding author. Mailing address: Department of Pathology, University of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, TX 78229-390. Phone: (210) 567-4088. Fax: (210) 567-2367. E-mail: jorgensen{at}uthscsa.edu.

Antimicrobial Agents and Chemotherapy, November 2000, p. 2962-2968, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Varon, E., Houssaye, S., Grondin, S., Gutmann, L., the Groupe des Observatoires de la Resistance du P, (2006). Nonmolecular Test for Detection of Low-Level Resistance to Fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50: 572-579 [Abstract] [Full Text]  
  • Azoulay-Dupuis, E., Bedos, J. P., Mohler, J., Moine, P., Cherbuliez, C., Peytavin, G., Fantin, B., Kohler, T. (2005). Activity of Gemifloxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model. Antimicrob. Agents Chemother. 49: 1046-1054 [Abstract] [Full Text]  
  • Jorgensen, J. H., Crawford, S. A., McElmeel, L. M., Whitney, C. G. (2004). Detection of Resistance to Gatifloxacin and Moxifloxacin in Streptococcus pneumoniae with the VITEK 2 Instrument. J. Clin. Microbiol. 42: 5928-5930 [Abstract] [Full Text]  
  • Yoo, B. K, Triller, D. M, Yong, C.-S., Lodise, T. P (2004). Gemifloxacin: A New Fluoroquinolone Approved for Treatment of Respiratory Infections. The Annals of Pharmacotherapy 38: 1226-1235 [Abstract] [Full Text]  
  • Christiansen, K. J., Bell, J. M., Turnidge, J. D., Jones, R. N. (2004). Antimicrobial Activities of Garenoxacin (BMS 284756) against Asia-Pacific Region Clinical Isolates from the SENTRY Program, 1999 to 2001. Antimicrob. Agents Chemother. 48: 2049-2055 [Abstract] [Full Text]  
  • Croisier, D., Etienne, M., Bergoin, E., Charles, P.-E., Lequeu, C., Piroth, L., Portier, H., Chavanet, P. (2004). Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy. Antimicrob. Agents Chemother. 48: 1699-1707 [Abstract] [Full Text]  
  • Morrissey, I., Tillotson, G. (2004). Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother 53: 144-148 [Abstract] [Full Text]  
  • Otani, T., Tanaka, M., Ito, E., Kurosaka, Y., Murakami, Y., Onodera, K., Akasaka, T., Sato, K. (2003). In Vitro and In Vivo Antibacterial Activities of DK-507k, a Novel Fluoroquinolone. Antimicrob. Agents Chemother. 47: 3750-3759 [Abstract] [Full Text]  
  • Kawamura, Y., Fujiwara, H., Mishima, N., Tanaka, Y., Tanimoto, A., Ikawa, S., Itoh, Y., Ezaki, T. (2003). First Streptococcus agalactiae Isolates Highly Resistant to Quinolones, with Point Mutations in gyrA and parC. Antimicrob. Agents Chemother. 47: 3605-3609 [Abstract] [Full Text]  
  • Allen, G. P., Kaatz, G. W., Rybak, M. J. (2003). Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 47: 2606-2614 [Abstract] [Full Text]  
  • Davies, T. A., Goldschmidt, R., Pfleger, S., Loeloff, M., Bush, K., Sahm, D. F., Evangelista, A. (2003). Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). J Antimicrob Chemother 52: 168-175 [Abstract] [Full Text]  
  • Bui, M.-H., Stone, G. G., Nilius, A. M., Almer, L., Flamm, R. K. (2003). PCR-Oligonucleotide Ligation Assay for Detection of Point Mutations Associated with Quinolone Resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47: 1456-1459 [Abstract] [Full Text]  
  • Yokota, S.-i., Sato, K., Kuwahara, O., Habadera, S., Tsukamoto, N., Ohuchi, H., Akizawa, H., Himi, T., Fujii, N. (2002). Fluoroquinolone-Resistant Streptococcus pneumoniae Strains Occur Frequently in Elderly Patients in Japan. Antimicrob. Agents Chemother. 46: 3311-3315 [Abstract] [Full Text]  
  • Houssaye, S., Gutmann, L., Varon, E. (2002). Topoisomerase Mutations Associated with In Vitro Selection of Resistance to Moxifloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46: 2712-2715 [Abstract] [Full Text]  
  • Takahata, M., Yamada, H., Morita, T., Furubou, S., Minami, S., Todo, Y., Watanabe, Y., Narita, H. (2002). Evaluation of T-3811ME (BMS-284756), a New Des-F(6)-Quinolone, for Treatment of Meningitis Caused by Penicillin-Resistant Streptococcus pneumoniae in Rabbits. Antimicrob. Agents Chemother. 46: 1760-1765 [Abstract] [Full Text]  
  • Davies, T. A., Evangelista, A., Pfleger, S., Bush, K., Sahm, D. F., Goldschmidt, R. (2002). Prevalence of Single Mutations in Topoisomerase Type II Genes among Levofloxacin-Susceptible Clinical Strains of Streptococcus pneumoniae Isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob. Agents Chemother. 46: 119-124 [Abstract] [Full Text]  
  • Weigel, L. M., Anderson, G. J., Facklam, R. R., Tenover, F. C. (2001). Genetic Analyses of Mutations Contributing to Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 3517-3523 [Abstract] [Full Text]  
  • Fass, R. J., Barnishan, J. (2001). Comparison of antimicrobial in vitro activities against Streptococcus pneumoniae independent of MIC susceptibility breakpoints using MIC frequency distribution curves, scattergrams and linear regression analyses. J Antimicrob Chemother 48: 609-615 [Abstract] [Full Text]  
  • Thornsberry, C., Karlowsky, J. A., Sahm, D. F., Jorgensen, J. H., Weigel, L. M., Swenson, J. M., Whitney, C. G., Tenover, F. C., Ferraro, M. J. (2001). Levofloxacin-Resistant Streptococcus pneumoniae: Second Look. Antimicrob. Agents Chemother. 45: 2183-2184 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»